Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program
ORLANDO, Fla., Feb. 26, 2018 -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer patients in Canada under a Special Access Program (SAP).
Amsterdam-based myTomorrows, an international leader in providing physicians access to experimental medicines, is conducting a similar program with Ampligen in Europe, where it is called an EAP, or Early Access Program.
In clinical trials in a variety of indications, approximately 100,000 doses of the experimental drug Ampligen have been administered, IV or intranasally, resulting in one of the most comprehensive safety profiles of a Toll-like receptor agonist. Toll-like receptors (TLRs) are a class of proteins that play a key role in activating the innate immune system.
- Published: 26 February 2018
- Written by Editor